image
Healthcare - Medical - Devices - NASDAQ - US
$ 16.85
-0.178 %
$ 1.12 B
Market Cap
-11.46
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TNDM stock under the worst case scenario is HIDDEN Compared to the current market price of 16.9 USD, Tandem Diabetes Care, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TNDM stock under the base case scenario is HIDDEN Compared to the current market price of 16.9 USD, Tandem Diabetes Care, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TNDM stock under the best case scenario is HIDDEN Compared to the current market price of 16.9 USD, Tandem Diabetes Care, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TNDM

image
$40.0$40.0$35.0$35.0$30.0$30.0$25.0$25.0$20.0$20.0$15.0$15.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
940 M REVENUE
25.74%
-99.1 M OPERATING INCOME
57.50%
-96 M NET INCOME
56.86%
24.2 M OPERATING CASH FLOW
176.16%
-23.5 M INVESTING CASH FLOW
72.61%
8.37 M FINANCING CASH FLOW
103.43%
283 M REVENUE
-22.20%
-582 K OPERATING INCOME
97.77%
755 K NET INCOME
103.25%
10.7 M OPERATING CASH FLOW
-59.98%
5.01 M INVESTING CASH FLOW
125.18%
2.3 M FINANCING CASH FLOW
150.94%
Balance Sheet Tandem Diabetes Care, Inc.
image
Current Assets 724 M
Cash & Short-Term Investments 438 M
Receivables 115 M
Other Current Assets 172 M
Non-Current Assets 243 M
Long-Term Investments 74.5 M
PP&E 163 M
Other Non-Current Assets 5.17 M
45.30 %11.84 %17.73 %7.70 %16.89 %Total Assets$967.7m
Current Liabilities 247 M
Accounts Payable 44.7 M
Short-Term Debt 18.2 M
Other Current Liabilities 184 M
Non-Current Liabilities 458 M
Long-Term Debt 455 M
Other Non-Current Liabilities 2.15 M
6.35 %26.13 %64.63 %Total Liabilities$704.6m
EFFICIENCY
Earnings Waterfall Tandem Diabetes Care, Inc.
image
Revenue 940 M
Cost Of Revenue 451 M
Gross Profit 490 M
Operating Expenses 589 M
Operating Income -99.1 M
Other Expenses -3.1 M
Net Income -96 M
1b1b800m800m600m600m400m400m200m200m00(200m)(200m)940m(451m)490m(589m)(99m)3m(96m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
52.07% GROSS MARGIN
52.07%
-10.54% OPERATING MARGIN
-10.54%
-10.21% NET MARGIN
-10.21%
-36.50% ROE
-36.50%
-9.92% ROA
-9.92%
-14.02% ROIC
-14.02%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Tandem Diabetes Care, Inc.
image
100m100m80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -96 M
Depreciation & Amortization 14.3 M
Capital Expenditures -19.2 M
Stock-Based Compensation 101 M
Change in Working Capital 0
Others 4.58 M
Free Cash Flow 4.99 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Tandem Diabetes Care, Inc.
image
Wall Street analysts predict an average 1-year price target for TNDM of $47.6 , with forecasts ranging from a low of $22 to a high of $75 .
TNDM Lowest Price Target Wall Street Target
22 USD 30.56%
TNDM Average Price Target Wall Street Target
47.6 USD 182.49%
TNDM Highest Price Target Wall Street Target
75 USD 345.10%
Price
Max Price Target
Min Price Target
Average Price Target
80807070606050504040303020201010May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership Tandem Diabetes Care, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
1.24 M USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
258 K USD 1
Bought
191 K USD 1
0-3 MONTHS
12.4 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Tandem Diabetes Care to Announce First Quarter 2025 Financial Results on April 30, 2025 SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2025 results after the financial markets close on Wednesday, April 30, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2025 financial and operating results. A live webcast of the call will be available on Tandem Diabe. businesswire.com - 2 weeks ago
TNDM Stock Gains on the Commercial Launch of Control-IQ+ Technology Tandem Diabetes launches Control-IQ+ technology commercially in the United States. Control-IQ+ is compatible with t:slim X2 insulin pump and Tandem Mobi System. zacks.com - 1 month ago
Tandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the United States SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced the United States commercial launch of Control-IQ+ technology, the latest generation of the company's advanced hybrid closed-loop algorithm. Control-IQ+, compatible with both the t:slim X2 insulin pump and Tandem Mobi System, is now available for people with type 1 diabetes ages 2 years and older and adults with type 2 diabetes. Pumps pre-loaded with. businesswire.com - 1 month ago
Reasons to Hold TNDM Stock in Your Portfolio for Now A robust product innovation and several strategic developments raise investors' optimism for Tandem Diabetes. zacks.com - 1 month ago
Tandem Diabetes Q4 Earnings Review: I Don't Share The Market's Skepticism Tandem Diabetes Care, Inc. released its Q4 and full-year 2024 earnings after the bell yesterday, and the market has given the stock the thumbs down. Shares are down >30% in trading today, despite a beat on revenues of $940m, and on EPS, with a return to positive cash flow. Guidance for 2025 is for revenues of ~$1bn — the growth rate does not seem to have impressed Wall Street, and Q4 underperformance issues also played a part. seekingalpha.com - 1 month ago
TNDM Stock Falls in Aftermarket Following Q4 Earnings and Revenue Miss Tandem Diabetes' Q4 top and bottom lines lag their respective estimate. However, the company experiences strong sales growth both in and outside the United States. zacks.com - 1 month ago
Tandem Diabetes Care, Inc. (TNDM) Q4 2024 Earnings Call Transcript Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Susan Morrison - Executive Vice President & Chief Administrative Officer John Sheridan - President & Chief Executive Officer Mark Novara - Executive Vice President & Chief Commercial Officer Leigh Vosseller - Executive Vice President & Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Steve Lichtman - Oppenheimer & Company Matt Miksic - Barclays Chris Pasquale - Nephron Research Larry Biegelsen - Wells Fargo Shagun Singh - RBC Mike Kratky - Leerink Partners Danielle Antalffy - UBS Jayson Bedford - Raymond James William Plovanic - Canaccord Genuity Mike Polark - Wolfe Research Matthew O'Brien - Piper Sandler Joshua Jennings - TD Cowen Jeff Johnson - Baird Travis Steed - Bank of America Operator Good day and welcome to the Tandem Diabetes Fourth Quarter and Year-End 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 1 month ago
Here's What Key Metrics Tell Us About Tandem Diabetes Care (TNDM) Q4 Earnings While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 1 month ago
Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Lags Revenue Estimates Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.27 per share a year ago. zacks.com - 1 month ago
Tandem Diabetes Care Announces Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter and fiscal year ended December 31, 2024 and provided its financial guidance for the year ending December 31, 2025. Fourth Quarter 2024 Financial Highlights compared to Fourth Quarter 2023 Achieved record sales as worldwide GAAP sales grew 44 percent to $282.6 million and worldwide non-GAAP sales(1) grew 21 percent. businesswire.com - 1 month ago
Tandem Diabetes Care (TNDM) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures Evaluate the expected performance of Tandem Diabetes Care (TNDM) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. zacks.com - 1 month ago
Tandem Diabetes Care Announces FDA Clearance of Control-IQ+ Automated Insulin Delivery Technology for People with Type 2 Diabetes SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--Control-IQ+ automated insulin delivery technology from Tandem Diabetes Care cleared by FDA for people with type 2 diabetes. businesswire.com - 1 month ago
8. Profile Summary

Tandem Diabetes Care, Inc. TNDM

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 1.12 B
Dividend Yield 0.00%
Description Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Contact 11075 Roselle Street, San Diego, CA, 92121 https://www.tandemdiabetes.com
IPO Date Nov. 14, 2013
Employees 2650
Officers Mr. Jean-Claude E. Kyrillos Executive Vice President & Chief Operating Officer Ms. Leigh A. Vosseller Executive Vice President, Chief Financial Officer & Treasurer Ms. Elizabeth Anne Gasser Executive Vice President and Chief Strategy & Product Officer Mr. Mark Novara Executive Vice President & Chief Commercial Officer Ms. Susan M. Morrison Executive Vice President & Chief Administrative Officer Ms. Shannon M. Hansen J.D. Executive Vice President, Chief Legal, Privacy & Compliance Officer and Secretary Dr. Jordan Pinsker M.D. Chief Medical Officer Mr. John F. Sheridan President, Chief Executive Officer & Director Mr. Rick A. Carpenter Chief Technical Officer Mr. Tom Fox Chief Human Resources Officer